Muscle spasticity refers to an abnormal increase in muscle tone or stiffness usually caused by damage to nerves in the brain or spinal cord that control voluntary movement. It is a common symptom of conditions such as cerebral palsy, multiple sclerosis, spinal cord injury, and stroke. Existing treatment options for muscle spasticity include botulinum toxin injections, baclofen, dantrolene, clonazepam, diazepam, and other muscle relaxants. However, there is significant room for improvement in efficacy and safety profiles with the currently available therapies.

The global Muscle Spasticity Market is estimated to be valued at Us$ 4942.44 Mn in 2023 and is expected to exhibit a CAGR Of 7.5% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

The muscle spasticity market is poised to accelerate in the coming years due to a rise in R&D activities focusing on development of novel treatment therapies. Several pharmaceutical companies are developing pipeline drugs targeting muscle spasticity with improved efficacy and safety. This is expected to boost the market growth during the forecast period.

Market Dynamics:

Increased adoption of novel therapies: Several pharmaceutical companies are conducting clinical trials for investigational drugs with novel mechanisms of action to treat symptoms of muscle spasticity. For instance, Blackmores Limited is evaluating BLM-210 as an oral therapy in phase II/III trials for the treatment of spasticity. This increases treatment options and drives the demand.

Rise in prevalence of conditions causing spasticity: According to recent statistics, the global prevalence of stroke is rising at an alarming rate. Stroke is a leading cause of acquired spasticity. The WHO projects that by 2030, stroke will be the fifth leading cause of death worldwide. Additionally, cerebral palsy affects 2.11 per 1,000 live births worldwide. This increasing disease burden will spur market growth over the forecast period.

Segment Analysis

Write one sentence explanation for each segment. The muscle spasticity market is dominated by the spasticity in lower extremities segment. This is because lower extremity spasticity is more common and affects mobility and daily activities more severely compared to upper extremity spasticity.

PEST Analysis

Political: Regulations supporting research and development activities in the muscle spasticity market are expected to have a positive impact.

Economic: Rising healthcare expenditure and growing disposable incomes are expected to support market growth.

Social: Increasing prevalence of neurological disorders and growing awareness about their treatment is driving the market.

Technological: Developments in therapeutic options like cannabinoids, nanotechnology and advanced delivery mechanisms are expanding treatment approaches.

Key Takeaways

The Global Muscle Spasticity Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2023 is estimated to be US$ 4942.44 Mn.

Regional analysis  :

North America is expected to dominate the global market during the forecast period. This is attributed to growing geriatric population, high healthcare spending, and rapid adoption of innovative treatment options in the region.

Key players  :

Key players operating in the muscle spasticity market are Blackmores Limited, Vitaco Holdings Limited, Integria Healthcare, Bioglan, Deep Blue Health (NZ) Co. Limited, Phytomed, NZ Herbals, and Sanderson. Blackmores Limited offers products for muscle spasticity symptoms relief through complementary medicines. Vitaco Holdings Limited provides health supplements containing herbal extracts and minerals for managing muscle spasms.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it